BioAtla (BCAB) Total Liabilities (2020 - 2026)
BioAtla (BCAB) posted quarterly Total Liabilities of $45.9 million for Q1 2026, up 21.55% year-over-year from $37.7 million in Q1 2025, and down 8.28% quarter-over-quarter from $50.0 million in Q4 2025.
BioAtla (BCAB) Total Liabilities (2020 - 2026) Analysis & Trends
BioAtla's Total Liabilities history runs 7 years deep, the most recent figure standing at $45.9 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 21.55% year-over-year to $45.9 million; the TTM figure through Mar 2026 stood at $45.9 million (up 21.55% YoY), while the FY2025 annual figure was $50.0 million, up 31.08% from the prior year.
- Total Liabilities for Q1 2026 stood at $45.9 million, down from $50.0 million in the prior quarter.
- The five-year high for Total Liabilities was $56.7 million in Q3 2023, with the low at $37.3 million in Q2 2024.
- The 5-year median for Total Liabilities is $45.9 million (2026), against an average of $45.2 million.
- The sharpest annual moves came in 2024 and 2025: Total Liabilities sank 32.39% in 2024, then jumped 31.08% in 2025.
- BioAtla's Total Liabilities stood at $45.4 million in 2022, then advanced by 7.91% to $49.0 million in 2023, then slipped by 22.11% to $38.2 million in 2024, then soared by 31.08% to $50.0 million in 2025, then dropped by 8.28% to $45.9 million in 2026.
- Business Quant data shows BCAB's Total Liabilities at $45.9 million in Q1 2026, $50.0 million in Q4 2025, and $47.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | BioAtla | 5.28 Mn | 5.28 Mn | - | 45.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.74 Mn |
| Mar 31, 2026 | 45.88 Mn |
| Dec 31, 2025 | 50.02 Mn |
| Sep 30, 2025 | 47.15 Mn |
| Jun 30, 2025 | 43.87 Mn |
| Mar 31, 2025 | 37.74 Mn |
| Dec 31, 2024 | 38.16 Mn |
| Sep 30, 2024 | 39.27 Mn |
| Jun 30, 2024 | 37.27 Mn |
| Mar 31, 2024 | 39.48 Mn |
| Dec 31, 2023 | 48.99 Mn |
| Sep 30, 2023 | 56.66 Mn |
| Jun 30, 2023 | 55.12 Mn |
| Mar 31, 2023 | 48.13 Mn |
| Dec 31, 2022 | 45.40 Mn |
| Sep 30, 2022 | 46.48 Mn |
| Jun 30, 2022 | 48.54 Mn |
| Mar 31, 2022 | 40.60 Mn |
| Dec 31, 2021 | 43.60 Mn |
| Sep 30, 2021 | 46.93 Mn |